Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) have earned an average recommendation of “Moderate Buy” from the fourteen brokerages that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and eleven have assigned a buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $42.40.

Several research analysts have recently weighed in on OLMA shares. Citigroup reduced their price target on shares of Olema Pharmaceuticals to $59.00 and set a “buy” rating for the company in a report on Tuesday, August 11th. JPMorgan Chase & Co. cut their price objective on shares of Olema Pharmaceuticals from $52.00 to $46.00 and set an “overweight” rating on the stock in a research report on Thursday, August 13th. Wall Street Zen lowered shares of Olema Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, July 25th. Guggenheim reduced their target price on shares of Olema Pharmaceuticals from $38.00 to $35.00 and set a “buy” rating for the company in a research note on Wednesday, May 13th. Finally, HC Wainwright lowered their target price on Olema Pharmaceuticals from $38.00 to $36.00 and set a “buy” rating for the company in a report on Tuesday, August 11th.

Insider Buying and Selling at Olema Pharmaceuticals

In other news, Director Cyrus Harmon sold 12,500 shares of the company’s stock in a transaction dated Thursday, July 23rd. The stock was sold at an average price of $11.58, for a total transaction of $144,750.00. Following the completion of the transaction, the director directly owned 715,270 shares of the company’s stock, valued at $8,282,826.60. This represents a 1.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 12.56% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Olema Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. Bain Capital Life Sciences Investors LLC boosted its position in Olema Pharmaceuticals by 24.3% during the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 8,508,641 shares of the company’s stock worth $212,716,000 after acquiring an additional 1,664,687 shares during the last quarter. Paradigm Biocapital Advisors LP raised its holdings in shares of Olema Pharmaceuticals by 11.0% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 7,544,172 shares of the company’s stock valued at $188,604,000 after purchasing an additional 750,000 shares during the last quarter. Janus Henderson Group PLC raised its holdings in shares of Olema Pharmaceuticals by 5.9% in the first quarter. Janus Henderson Group PLC now owns 7,108,488 shares of the company’s stock valued at $106,013,000 after purchasing an additional 398,294 shares during the last quarter. Jupiter Topco LLC acquired a new stake in shares of Olema Pharmaceuticals in the second quarter valued at approximately $88,803,000. Finally, BlackRock Inc. bought a new stake in shares of Olema Pharmaceuticals in the second quarter worth $84,001,000. Institutional investors own 91.78% of the company’s stock.

Olema Pharmaceuticals Trading Down 2.4%

NASDAQ OLMA opened at $10.43 on Tuesday. The firm has a market cap of $912.62 million, a P/E ratio of -4.92 and a beta of 2.03. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.86 and a quick ratio of 8.86. The stock’s 50-day moving average is $11.35 and its 200-day moving average is $14.71. Olema Pharmaceuticals has a one year low of $5.36 and a one year high of $36.26.

Olema Pharmaceuticals (NASDAQ:OLMA) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.06). Sell-side analysts anticipate that Olema Pharmaceuticals will post -2.43 earnings per share for the current fiscal year.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.